VITA Financial Statements From 2010 to 2025
| VTIAF Stock | USD 6.38 0.00 0.00% |
Check VITA 34 financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VITA 34's main balance sheet or income statement drivers, such as , as well as many indicators such as . VITA financial statements analysis is a perfect complement when working with VITA 34 Valuation or Volatility modules.
VITA |
VITA 34 AG Company Return On Equity Analysis
VITA 34's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current VITA 34 Return On Equity | -0.37 |
Most of VITA 34's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VITA 34 AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, VITA 34 AG has a Return On Equity of -0.3731. This is 98.44% lower than that of the Healthcare sector and significantly lower than that of the Medical Care Facilities industry. The return on equity for all United States stocks is 20.35% higher than that of the company.
VITA 34 AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining VITA 34's current stock value. Our valuation model uses many indicators to compare VITA 34 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VITA 34 competition to find correlations between indicators driving VITA 34's intrinsic value. More Info.VITA 34 AG is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VITA 34's earnings, one of the primary drivers of an investment's value.About VITA 34 Financial Statements
VITA 34 stakeholders use historical fundamental indicators, such as VITA 34's revenue or net income, to determine how well the company is positioned to perform in the future. Although VITA 34 investors may analyze each financial statement separately, they are all interrelated. For example, changes in VITA 34's assets and liabilities are reflected in the revenues and expenses on VITA 34's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in VITA 34 AG. Please read more on our technical analysis and fundamental analysis pages.
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany. Vita 34 operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange. It employs 775 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in VITA Pink Sheet
VITA 34 financial ratios help investors to determine whether VITA Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VITA with respect to the benefits of owning VITA 34 security.